clinical trial · NCT05671835
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary FibrosisTTI-101Placebo
brief summary
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
started
May 15, 2023
primary completion
Aug 14, 2025
completion
Aug 14, 2025
last updated
Sep 30, 2025
official title
REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol